Trial Profile
Response Assessment to Pembrolizumab With Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging- A Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary) ; Pembrolizumab
- Indications Glioblastoma
- Focus Diagnostic use
- 06 Jun 2023 Planned primary completion date changed from 30 Aug 2023 to 31 Dec 2023.
- 03 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2021 Planned End Date changed from 30 May 2023 to 30 May 2024.